# Kidney Protection During Surgery on the Thoracoabdominal Aorta: A Systematic Review

## Authors

Mr James Thomas Bennett ACP, MSc, BSc (Hons)<sup>1,2</sup> Mrs Sarah Shirley ACP, MSc, BSc (Hons)<sup>1,2</sup> Professor Patricia Murray RGN, PhD, BSc<sup>2</sup> Dr Bettina Wilm Dr rer nat<sup>2</sup> Professor Mark Field DPhil (Oxon), FRCS (C-Th)<sup>1,2</sup>

## **Associated Institutions**

- 1. Liverpool Heart and Chest Hospital NHS Trust, Liverpool, England
- 2. The University of Liverpool, Faculty of Health and Life Sciences, Liverpool, England

# **Corresponding Author**

Mr James Thomas Bennett James.Bennett@lhch.nhs.uk Perfusion Department, Theatres, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, L14 3PE, United Kingdom.

**Keywords:** Thoracoabdominal Surgery, Aorta, Kidney, Protection, Renal, Perfusion **Total Word Count:** 4952 (9285 including title page, abstract, tables, figure legends and references)

# Authorship Criteria and Responsibilities:

JB: Conception and design, acquisition of data, analysis and interpretation of data, drafting the manuscript
SS: Conception and design, acquisition of data, drafting the manuscript
PM: Revising manuscript
BW: Drafting the manuscript, revising manuscript
MF: Revising manuscript

#### Abstract

**Background:** Acute kidney injury (AKI) is a common complication of surgery to repair the thoracoabdominal aorta, and is associated with risks of dialysis and early mortality. Renal ischaemia, initiated by clamping of the suprarenal aorta, is a major cause. Consequently, perfusion techniques are commonly used to sustain renal blood flow or facilitate hypothermic kidney preservation during surgery. This systematic review provides a comprehensive assessment of renal and mortality outcomes by perfusion techniques, to evaluate their ability to provide effective kidney protection.

**Methods & Results:** Searches of PubMed, Web of Science, ClinicalTrials.gov and ClinicalTrialsRegister.EU were conducted to identify relevant studies published from 1995 to 2024. Included studies were quality assessed, and data were extracted by perfusion techniques. Outcomes of the highest quality studies were used to synthesise a narrative discussion.

Forty-five studies were included in our analysis, featuring three extracorporeal strategies: Left heart bypass (LHB; n=24), cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA; n=19), and partial cardiopulmonary bypass (pCPB; n=12). Three categories of selective renal perfusion strategy were identified: Warm blood, cold blood and cold crystalloid. Our analysis identified operative mortality as 0-23.4% following LHB, 2.2-12.5% following DHCA and 0-42.1% following pCPB. The incidence of renal replacement therapy was 0-40.0% following LHB, 0-15.0% following DHCA and 0-22.2% following pCPB.

**Conclusions:** Strong evidence supports the use of distal aortic perfusion (DAP) with LHB or pCPB, to reduce the risks of dialysis and operative mortality associated with aortic cross clamping. Furthermore, when DAP cannot prevent kidney ischaemia, adjunctive perfusion of the renal arteries with cold histidine-tryptophan-ketoglutarate (HTK) can reduce the risk of AKI. However, no professional guidance on the management of HTK exists, and rates of AKI remain high despite its use. Selective renal perfusion with warm blood is identified as a risk factor for AKI and operative mortality. DHCA is associated with low rates of AKI, warranting further prospective investigation. Finally, intravascular haemolysis and myoglobinaemia are acknowledged as important risk factors that require urgent research to address the problem of AKI.

#### Non-standard abbreviations and acronyms

- AKI- Acute kidney injury
- AKIN- Acute kidney injury network
- ATN- Acute tubular necrosis
- ATP- Adenosine Triphosphate
- CPB- Cardiopulmonary bypass
- DAP- Distal aortic perfusion
- DHCA- Deep hypothermic circulatory arrest
- ECC- Extracorporeal circulation
- EU- European Union
- HLM- Heart lung machine
- IRI- Ischaemia-reperfusion injury
- KDIGO- Kidney disease improving global outcomes
- LHB- Left heart bypass
- pCPB- Partial cardiopulmonary bypass
- POS- Prospective observational study
- PRISMA- Preferred reporting items for systematic reviews and meta-analyses
- QOL- Quality of Life
- RCT- Randomised controlled trial
- RIFLE- Risk, Injury, Failure, Loss, End Stage Renal Disease
- **ROB-** Risk of bias
- ROS- Retrospective observational study
- RRT- Renal replacement therapies
- SACC- Simple aortic cross clamping
- SRP- Selective renal perfusion
- SWiM- Synthesis without meta-analysis
- TAA- Thoracoabdominal aorta

#### Introduction

#### Background

Surgical repair of the thoracoabdominal aorta (TAA) (figure 1) is a life-saving procedure for the treatment of aneurysms that present patients with high risks of rupture or visceral organ ischaemia<sup>1, 2</sup>. However, this complex undertaking can expose patients to several physiological challenges, including ischaemiareperfusion injury, intravascular haemolysis, and acute inflammation<sup>3-5</sup>. Such factors can contribute to the development of post-operative organ dysfunction, and may manifest as disorders such as acute kidney injury (AKI), paraplegia, stroke or pulmonary dysfunction<sup>6</sup>. Reducing the incidence of such complications is essential to improve patient quality of life (QOL) following surgery<sup>6</sup>.

Intra-operative organ protection strategies can be used to improve patient care<sup>7</sup>. For instance, the use of distal aortic perfusion (DAP), cerebrospinal fluid drainage and intra-operative neuromonitoring can ensure effective spinal cord protection, and reduce the risk of post-operative paraplegia<sup>8-12</sup>. In contrast, providing effective intra-operative renal protection has proven a more elusive ambition; AKI has been reported to affect the majority of patients who undergo TAA repair<sup>13, 14</sup>. As AKI is a significant predictor of early mortality<sup>15</sup>, establishing effective renal protection strategies is imperative to improve patient QOL and operative survival.



Figure 1. Crawford extents of the thoracoabdominal aorta.

#### Acute Kidney Injury

AKI denotes an abrupt decline in renal function, diagnosed by an elevated serum creatinine concentration and/or decreased urine output (table 1)<sup>16, 17</sup>. Several classification systems exist, including KDIGO, RIFLE and AKIN, to score the severity of AKI from mild to severe<sup>18</sup>. Severe AKI typically requires the use of renal replacement therapies (RRT), such as haemodialysis, and is associated with the greatest risk of operative mortality<sup>15, 19-22</sup>. However, even mild AKI can increase a patient's risk of early death<sup>18</sup>. Furthermore, AKI

can progress towards chronic kidney disease, with up to 7% of TAA patients requiring RRT following hospital discharge<sup>22-25</sup>. Understanding how AKI develops is essential to design targeted strategies for its prevention<sup>26</sup>.

Tal	ble 1: KDIGO AKI classification criteria for	adults <sup>17</sup>
Stage	Serum creatinine concentration	Urine output
1	1.5-1.9 times baseline	<0.5ml/kg/h for 6-12 hours
	OR ≥0.3mg/dl (≥26.5mmol/l)	
	increase	
2	2.0-2.9 times baseline	<0.5ml/kg/h for ≥12 hours
3	3.0 times baseline	<0.3ml/kg/h for ≥24 hours
	OR	OR
	≥4.0mg/dl (≥353.6mmol/l)	Anuria for ≥12 hours
	OR	
	Initiation of renal replacement	
	therapy	

The pathophysiology of AKI is complex and multifactorial<sup>27</sup>. However, extended renal ischaemia, instigated by clamping of the suprarenal aorta, is the primary cause in the context of TAA surgery<sup>7, 26, 28</sup>. Clamping may be necessary to facilitate aortic transection and repair, but causes an abrupt pause in renal blood flow that can materialise as acute tubular necrosis and localised inflammation<sup>26</sup>. Additionally, intravascular haemolysis, caused by shearing forces within extracorporeal circuits, can cause renal endothelial dysfunction and contribute to kidney hypoperfusion<sup>4, 29, 30</sup>.

Renal ischaemia generates hypoxic conditions that deplete intracellular ATP and inhibit essential processes in all segments of the nephron<sup>31</sup>. Proximal tubular epithelial cells, however, are notably vulnerable to hypoxic injury, due to their dependence on oxidative phosphorylation to sustain the energetic processes of tubular reabsorption and secretion<sup>16, 27, 32, 33</sup>. Severe or extended hypoxia can induce cell death through apoptosis and necrosis<sup>13, 16, 31</sup>. Furthermore, subsequent re-perfusion of the hypoxic kidney, on removal of the aortic cross-clamp, can amplify the mitochondrial production of reactive oxygen species and activate pro-inflammatory pathways<sup>16, 34, 35</sup>. These processes can culminate in cell damage and dysfunction, collectively known as ischaemia-reperfusion injury (IRI), and inhibit glomerular filtration rate<sup>27, 31, 35</sup>.

# Intra-operative Kidney Protection

Open repair of the TAA can be performed with the independent use of 'simple aortic cross clamping' (SACC), in which no systemic circulatory support strategies are employed. However, with SACC, the period of suprarenal clamping directly corresponds to the duration of renal ischaemia, and augments the risk of AKI<sup>21, 36, 37</sup>. Additionally, SACC is related to an increased risk of neurological injury<sup>38, 39</sup>. Expedient surgery is therefore required to minimise organ ischaemia, and prevent AKI.

More commonly, extracorporeal perfusion strategies are employed to attenuate renal IRI through oxygenation or hypothermia (figure 2). Strategies of left heart bypass (LHB) or partial cardiopulmonary bypass (pCPB) can provide DAP and supply the kidneys with normothermic, oxygen-rich blood during surgery<sup>28, 37</sup>. Both strategies are analogous in their ability to perfuse the distal aorta, and their reliance on sustained cardiac output and ventilation to perfuse arteries proximal to the aortic cross clamp. However, they differ in their respective cannulation sites and perfusion techniques: LHB involves the active shunting of oxygenated blood from the left side of the heart to the distal aorta; pCPB utilises blood drained from the venous system, so requires an oxygenator to facilitate gas exchange. DAP can provide continuous renal blood flow during repairs of the descending thoracic aorta (DTA) or Crawford extent I aneurysms. However, flow is interrupted during the repair of more extensive aneurysms that encompass the renal arteries. Full cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA) is an alternative strategy that may be used to provide organ protection and create a bloodless surgical field. DHCA is commonly reserved for emergency TAA repairs, or cases in which the application of an aortic cross clamp is not feasible.





All circulatory support strategies can be augmented with the use of selective renal perfusion (SRP); a technique that involves direct cannulation and perfusion of the renal arteries with warm blood, cold blood or cold crystalloid fluids. 'Warm' SRP, delivered at normothermia to mild hypothermia, is intended to maintain renal oxygen delivery; 'cold' SRP, routinely cooled to approximately 4°C, aims to reduce renal oxygen consumption<sup>40</sup>. Warm perfusion solutions therefore contain blood to facilitate oxygen delivery, whereas cold solutions can be composed of blood and/or crystalloid fluids. Crystalloid perfusates are commonly enriched with additives designed to increase buffering capacity, maintain cell membrane integrity or reduce inflammation<sup>13</sup>.

A 2010 report from the American College of Cardiology Foundation & American Heart Association recommends that clinicians consider the use of cold blood or crystalloid kidney perfusion during renal artery exposure<sup>39</sup>. Beyond this recommendation, limited evidence-based guidance exists to inform best practice in renal protection. A comprehensive evaluation of intra-operative perfusion techniques is required to establish the efficacy of contemporary renal protection strategies and direct future research and innovation.

This systematic review evaluates published renal and mortality outcomes following TAA repair, to synthesise a narrative discussion on the efficacy of renal protection strategies. Our objectives are:

- (1) To catalogue the findings of relevant studies published between the years 1995 and 2024.
- (2) To assess the quality of evidence regarding the use of all featured perfusion techniques.
- (3) To evaluate the ability of each perfusion technique to ameliorate AKI and operative mortality.
- (4) To identify important areas of research for future innovation in renal protection.

# **Materials and Methods**

# Study Protocol and Literature Search

Our protocol was prospectively registered with Prospero (CRD42020166428) and designed in accordance with PRISMA and SWiM recommendations. Searches of PubMed, Web of Science, ClinicalTrials.gov and the EU Clinical Trials Register were conducted to identify relevant English language studies published between 1995 and 2024. Studies were screened against eligibility criteria at the abstract and full-text stages. Included studies were required to feature open surgery on the TAA, an adult patient population, the predominant use of one or more circulatory support strategies, and reporting of post-operative renal outcomes. Studies containing the predominant use of endovascular techniques or type A dissection repairs were excluded. Clinical trials and observational studies were included, whereas single case studies and non-primary publications were excluded. Full literature search terms are provided in table 2.

Table 2: Full Liter	rature Search Terms
Information Sources	PubMed
	Web of Science
	ClinicalTrials.gov
	EU Clinical Trials Register
Date range searched	01/01/1995 to 28/06/2024
Types of study to be included	Clinical Trial reports, prospective observational studies and retrospective observational studies.
Database Search Queries	PubMed:
	((((Thoracoabdominal) OR (TAAA)) AND ((Perfusion) OR (CPB) OR (Bypass)) AND ((Renal) OR (Kidney) OR (AKI) OR (Haemodialysis) OR (Dialysis) OR (Creatinine) OR (GFR) OR (eGFR) OR (Glomerular))) NOT ((Endovascular Techniques[MeSH Terms]))
	Clinicaltrials.gov:
	Condition or disease: Thoracoabdominal Aortic Aneurysm
	Other Terms: (Renal) AND (Repair OR Surgery) NOT (Endovascular OR Stent)
	Status: Completed OR Unknown status
	Age Group: Adult (18-64) OR Older adult (65+)
	Sex: All
	EU Clinical Trials Register:
	Search Terms: Thoracoabdominal AND Renal NOT (Endovascular OR Stent) Age Range: Adult Trial Status: Completed
	Web of Science:
	(((ALL=(Thoracoabdominal OR TAAA)) AND ALL=(Perfusion OR CPB OR Bypass)) AND ALL=(Renal OR Kidney OR AKI OR Haemodialysis OR dialysis OR Creatinine OR GFR OR glomerular)) NOT TS=(Endovascular Techniques)

# Data Extraction and Analysis

Data extraction was performed by two reviewers (JB & SS) to ensure consensus in recorded outcomes. Study characteristics, patient demographics, intervention details and clinical outcomes were extracted. Endpoints included the incidence of post-operative RRT, AKI, 30-day mortality and in-hospital mortality. Where appropriate, patient subgroups were identified within studies according to the predominant perfusion strategies used. Data were extracted and presented by patient subgroups, to facilitate the comparison of renal and mortality outcomes by the techniques used. Meta-analysis was not undertaken due to the recognised variability in patient characteristics, operative techniques and reported outcomes present in this area of research.

# Quality and Risk of Bias Assessment

A quality and risk of bias (QROB) assessment was undertaken according to nine risk of bias domains:

- Focus on renal protection
- Study design and methodology
- General representativity/homogeneity of baseline patient characteristics
- Risk of participant duplication across multiple studies
- Appropriate use of statistical analysis
- Certainty of findings, in regard to sample size and magnitude of effect
- Standardisation of operative procedures
- Detailed account of perfusion techniques
- Identified conflicts of interest

Studies were judged to present 'no concerns', 'minor concerns' or 'major concerns' for each QROB criterion. For single cohort observational studies, a judgement of 'not applicable' was used in regard to the 'appropriate use of statistical analysis'. The overall quality of each study was summarised as 'very high', 'high', 'moderate' or 'low', based on the number of respective concerns identified (table 3). Following the QROB assessment, a narrative discussion was synthesised, prioritising the findings of the highest quality studies.

Table 3: Gra	ding criteria used in quality and risk o	f bias analysis
Overall quality	Number of minor concerns	Number of major or not applicable concerns
Very High	≤1	0
High	2-3	0
Moderate	≤3	1
Low	>3	≥1





Figure 3. PRISMA flow diagram of the literature search and screening process.

## Study Characteristics & Quality Assessment

45 of 589 identified studies were suitable for inclusion, featuring 3 clinical trials, 7 prospective observational studies (POS) and 35 retrospective observational studies (ROS), representing 6,622 operative cases. A heatmap of participant characteristics is presented in figure 4. 68 study subgroups were identified by the predominant perfusion strategy used. 22 studies featured multiple patient cohorts, enabling the direct comparison of alternate perfusion strategies, whereas 23 studies featured a single patient group.

The QROB assessment showed that five studies were of 'very high quality', three studies of 'high quality', ten studies of 'moderate quality' and twenty-seven of 'low quality' (figure 5). No significant conflicts of interest were identified.

# Perfusion Techniques

# **Circulatory Support**

Three strategies of systemic circulatory support were identified within the 45 included studies (table 4). The exclusive use of LHB was identified in 33 subgroups (24 studies), DHCA in 16 subgroups (15 studies) and pCPB in 13 subgroups (12 studies). 9 subgroups featured mixed perfusion techniques, in which the predominant strategies used were LHB (6 subgroups; 5 studies) and pCPB (3 subgroups; 3 studies). SACC was used exclusively in 7 subgroups (7 studies).

# Selective Renal Perfusion

SRP was employed as an adjunct to LHB in 26 subgroups (20 studies), utilising cold crystalloid solutions in 11 subgroups (9 studies), warm blood in 8 subgroups (8 studies) and cold blood in 7 subgroups (7 studies) (table 4). SRP was used alongside pCPB in 9 subgroups (8 studies), including warm blood in 8 subgroups, and cold crystalloid in 1. Five subgroups featured SACC with the adjunctive use of cold crystalloid SRP. Of five subgroups that utilised SRP with DHCA, three used cold blood and one used a cold crystalloid solution. The contents of crystalloid-based renal perfusates are displayed in table 5.

					Patie	ent Character	ristics				
			Pre-					Crawf	ord TAA Exte	ent (%)	
Study	Sample Size	Emergency (%)	operative CKD (%)	Male (%)	Average Age (Yrs)	DTA (%)	I	П	ш	IV	V
Alfonsi et al. (2018)	217	8.8		68.2	60.2	0.0	30.4	52.1	11.5	4.6	1.4
Bavaria <i>et al.</i> (1995)	81	30.9					32.1	22.2	9.9	9.9	
Bianchi et al. (2022)	100	0.0	17.0	64.0	64.0	0.0	16.0	29.0	32.0	18.0	5.0
Cinà <i>et al.</i> (2002)	121	18.2				0.0	14.0	19.8	23.1	43.0	0.0
Conrad et al. (2011)	179		9.9			0.0	40.8	17.3	41.9	0.0	0.0
Corvera <i>et al.</i> (2012)	93	5.4	15.1	72.0	60.1	29.0	24.7	39.8			0.0
Fehrenbacher et al. (2007a)	173	10.4		67.0	66.1	36.4	15.6	28.3	11.6	8.1	0.0
Fehrenbacher et al. (2007b)	33	6.1	24.2	72.7	70.0	0.0	0.0	0.0	57.6	42.4	0.0
Fehrenbacher et al. (2010)	343	13.1	15.5	63.6	66.0	28.6	20.1	32.4	9.3	9.6	0.0
Fleck et al. (2005)	17		18.0	58.8	67.2	0.0	11.8	70.6	17.6	0.0	0.0
Harky <i>et al.</i> (2021)	430	35.1	14.0	66.0	63.0	36.5			63.5		
Hassoun et al. (2004)	81		25.9	59.3		0.0	9.9	51.9	16.0	19.8	2.5
Henmi <i>et al.</i> (2022)	294		84.6	71.5	63.4	0.0	8.5	34.4	42.2	10.5	0.0
Huang <i>et al.</i> (2022)	26			85.0	50.0		0.0	69.2	3.8	0.0	26.9
Jacobs et al. (1998)	73	23.3	5.5	63.0	59.0	0.0	37.0	38.4	11.0	13.7	0.0
Kahlberg et al. (2021)	90		30.0	68.9	65.1	0.0	11.1	36.7	27.8	24.4	0.0
Karlsson et al. (2022)	33					0.0					
Kawaharada <i>et al.</i> (2002)	37					0.0	10.8	35.1	27.0	27.0	0.0
Kawaharada <i>et al.</i> (2004)	100	0.0		70.0	61.0	0.0	24.0	24.0	35.0	17.0	0.0
Koksoy <i>et al.</i> (2002)	30	16.7	26.7			0.0	0.0	100.0	0.0	0.0	0.0
Kouchoukos et al. (2013)	243	7.4		49.0	64.0	0.0	25.9	39.9	34.2	0.0	0.0
Kouchoukos et al. (2015)	69		13.0	77.0	54.0	0.0	18.8	59.4	21.7	0.0	0.0
Kouchoukos et al. (2019)	285	6.7	15.4		64.0	0.0	25.3	37.5	36.5	0.7	0.0
Kulik <i>et al.</i> (2011)	218	8.3	13.8	50.0	63.0	0.0	26.1	41.7	32.1	0.0	0.0
Kunihara <i>et al.</i> (2009)	17			59.0	64.0	0.0	17.6	29.4	23.5	23.5	5.9
Kunihara <i>et al.</i> (2021)	182		27.5	66.4	68.0	0.0	30.8	18.7	23.6	9.3	17.6
Leijdekkers <i>et al.</i> (1999)	11					0.0	0.0	100.0	0.0	0.0	0.0
LeMaire et al. (2002)	1220		25.0			0.0	34.7	30.4	16.5	18.4	0.0
LeMaire et al. (2009)	172	2.9	15.0	62.0	62.5	0.0	0.0	91.9	8.1	0.0	0.0
Mastroroberto et al. (1999)	19	100.0			67.1	0.0	63.2	15.8	5.3	15.8	0.0
Mkalaluh <i>et al.</i> (2018)	38	21.1	23.7	42.1	54.4	0.0	31.6	57.9	7.9	2.6	0.0
Morishita <i>et al.</i> (1999)	73	9.6				0.0	12.3	17.8	46.6	23.3	0.0
Nishi <i>et al.</i> (2004)	17	5.9	11.8	65.0		0.0	52.9	47.1	0.0	0.0	0.0
Palombo et al. (2004)	7			71.4	68.0	0.0	28.6	57.1	14.3	0.0	0.0
Safi <i>et al.</i> (1996)	234		24.0	63.7		3.0	32.9	42.3			0.0
Schepens et al. (1999)	258	14.7	5.8	73.6	65.4	0.0	15.1	43.4	27.5	14.0	0.0
Soukiasian et al. (2005)	59					16.9					
Sun <i>et al. (2024)</i>	40	0.0	_	40.0	33.0	0.0	5.0	5.0	42.5	30.0	17.5
Tshomba et al. (2014)	84		30.0	77.4	66.5	0.0	0.0	29.8	38.1	32.1	0.0
Wahlgren et al. (2017)	90		8.0	78.8	60.0	47.8	12.2	21.1	15.6	1.1	2.2
Weiss et al. (2012)	240	20.4	10.0	56.0	62.6	30.0	32.5	10.8	12.9	13.8	0.0
Welborn <i>et al.</i> (2000)	37		57.0			0.0	16.2	27.0	10.8	21.6	0.0
Wongkornrat et al. (2015)	200	9.5		73.5	65.1	0.0	12.0	41.0	25.5	5.0	16.5
Zhang et al. (2016)	81		-	75.3	39.4	0.0	0.0	100.0	0.0	0.0	0.0
Zhang et al. (2019)	190		2.2	74.7	39.5	0.0	0.0	100.0	0.0	0.0	0.0
Key:											
	Colour scale	e represents :	10th to 90th	percentiles.	CKD- Modera	ate or severe	e chronic kidr	ney disease;	DTA- Descen	ding thoracio	aorta; TAA-
		Thoraco	abdominal a	orta. Averag	e age = repo	rted mean o	r median. Gr	ey cells indic	ate lack of re	eporting.	
104											
1001 90th											

Figure 4: Heatmap of reported patient characteristics from all included studies.

Churche				Ris	k of Bias Dom	ains			c	Overall
Study	D1	D2	D3	D4	D5	D6	D7	D8	D9	Quality
Safi <i>et al.</i> (1996)										Very High
Koksoy <i>et al.</i> (2002)										Very High
Lemaire et al. (2009)										Very High
Kahlberg et al. (2021)										Very High
Henmi <i>et al.</i> (2022)										Very High
LeMaire et al. (2002)		0		$\bigcirc$	$\bigcirc$		$\bigcirc$	$\bigcirc$		High
Hassoun et al. (2004)		•			$\bigcirc$					High
Conrad et al. (2011)	•	•								High
Bavaria et al. (1995)	0	•						8		Moderate
Morishita et al. (1999)	$\bigcirc$		8							Moderate
Schepens et al. (1999)	•		8							Moderate
Kunihara et al. (2009)										Moderate
Weiss et al. (2012)				$\checkmark$	$\sim$			8		Moderate
Tshomba et al. (2014)	$\bigcirc$			$\checkmark$	$\checkmark$		8			Moderate
Wahlgren et al. (2017)			$\otimes$		$\checkmark$		$\checkmark$		$\checkmark$	Moderate
Zhang et al. (2019)				8						Moderate
Harky et al. (2021)			8							Moderate
Karlsson <i>et al</i> . (2022)	•					$\otimes$				Moderate
Jacobs et al. (1998)		$\bigcirc$			8	8	$\bigcirc$	$\bigcirc$		Low
Leijdekkers et al. (1999)		$\bigcirc$			8	8	$\bigcirc$			Low
Mastroroberto et al. (1999)			$\otimes$		•	$\otimes$		$\otimes$		Low
Welborn <i>et al.</i> (2000)	$\bigcirc$	$\bigcirc$	8	$\bigcirc$				8		Low
Cina et al. (2002)	•		$\otimes$		8	8	8	8		Low
Kawaharada et al. (2002)	8			8						Low
Kawaharada <i>et al.</i> (2004)			8	$\mathbf{N}$						Low
Nishi <i>et al.</i> (2004)				$\bigcirc$	$\mathbf{\Theta}$	Ø	$\sim$		$\checkmark$	Low
Palombo et al. (2004)					8	8	$\sim$			Low
Fleck et al. (2005)	×		<b>S</b>	$\sim$			$\sim$			Low
Soukiasian <i>et al.</i> (2005)			$\otimes$		$\sim$			8	$\sim$	Low
Fehrenbacher <i>et al</i> . (2007a)			$\otimes$	$\mathbf{N}$			$\sim$	$\sim$		Low
Fehrenbacher et al. (2007b)			8			<b>S</b>				Low
Fehrenbacher et al. (2010)										Low
Kulik et al. (2011)										Low
Corvera et al. (2012)		×		×						Low
Kouchoukos et al. (2013)				×			$\leq$	$\mathbf{\mathbf{i}}$		Low
Kouchoukos et al. (2015)			×	×						Low
Wongkornrat <i>et al.</i> (2015)	×	<b>2</b>								Low
Zhang et al. (2016)	×			$\leq$			$\leq$			Low
Altonsi et al. (2018)									$\leq$	LOW
Ivikalalun et dl. (2018)						<b>M</b>			$\leq$	LOW
Kouchoukos et al. (2019)										Low
Kuninara <i>et di</i> . (2021)	×			$\leq$			×			Low
Huang et al. (2022)							$\leq$			LOW
Sup et al. (2022)								<b>2</b>		Low
Domains: D1 Focus on ro					- Patient char	actoristics: D4	- Rick of parti		tion across str	udies: D5
Appropriate statistical analy	/sis; D6- Certa	ainty of findin	esign and men gs; D7- Standa	ardisation of o	perative proc	edures; D8- D	etailed perfus	ion strategies	; D9- Conflicts	of interest
Judgem	nent:		$\checkmark$	No concerns		Minor concerns	$\otimes$	Major concerns		Not applicable

Figure 5: Visualisation of QROB assessment for all included studies.

				Table 4. S	tudy Charac	teristics and Cl	inical Out	comes					
					AKI E	Indpoint			Mortali	ity Endpoint			
Study	Design	Sample Size	Systemic Strategy	SRP Technique	RRT	Other	АКІ (%)	Sig.	30 Day	In Hospital	Mortality (%)	Sig.	Additional Evidence of Renal Protection
Bavaria <i>et al</i> .	ROS	45	LHB				13.3	NS		•	6.7	<0.05	
(1995) <sup>41</sup>	105	36	SACC		·		24.2	115		·	22.2	<b>\0.05</b>	
		90	LHB				6.7						1
Safi <i>et al.</i> (1996) <sup>42</sup>	ROS	58	LHB	Warm Blood		•	29.3						
least at al		33	LHB	Warm Blood <sup>1</sup>			9.0						
(1998) <sup>43</sup>	POS	40	LHB	Warm Blood <sup>2</sup>	•		5.0			•	8.0		
		6	LHB	Warm Blood			33.0						
Leijdekkers <i>et al.</i> (1999) <sup>44</sup>	POS	5	LHB	Warm blood	•		40.0						
Mastroroberto <i>et</i> al. (1999) <sup>45</sup>	ROS	19	рСРВ			•	31.6		•		42.1		
		41	pCPB <sup>3</sup>	Warm Blood			4.9				17.0		$\checkmark$
Morishita <i>et al.</i> (1999) <sup>46</sup>	ROS	22	pCPB <sup>4</sup>	Warm Blood		•	4.5	0.01	•		5.0		$\checkmark$
· ·		10	SACC				20.0				10.0		
Schepens <i>et al.</i>		123	SACC	Cold Crystalloid			10.9				14.6		
(1999)47	ROS	135	LHB	Cold Crystalloid	•		5.9			•	5.9	0.02	
Welborn <i>et al.</i>		12	LHB				25.0				0.0		
(2000) <sup>34</sup>	POS	16	SACC			•	44.0			•	11.0		

Cina et al		43	SACC	Cold Crystalloid		3.0				26.6		
(2002) <sup>48</sup>	POS	78	LHB (59%), SACC (41%)	Cold Blood	•	16.0			•	5.7	0.01	
Kawaharada <i>et</i> al. (2002) <sup>49</sup>	ROS	37	рСРВ	Warm Blood	•	22.2		•		14.8		
Koksoy <i>et al.</i> (2002) <sup>40</sup>	СТ	16	LHB	Warm Blood	•	6.3	NS		•	6.3		,
		14	LIID	colu crystallolu		0.0				7.1		v
LeMaire <i>et al.</i>	ROS	78	SACC	Cold Crystalloid	•	3.0	NS			6.0		
(2002)50		34	LHB	Warm Blood		13.0				22.0		√
Hassoun <i>et al</i> .		44	LHB	Cold Blood		23.4				21.0		
(2004) <sup>51</sup>	ROS	37	LHB	Warm Blood	•	21.6		•		46.0	0.02	
Kawaharada <i>et</i> al. (2004) <sup>52</sup>	ROS	100	pCPB (99%), SACC (1%)	Warm Blood	•	16.2		•		5.4		
Nishi <i>et al.</i>	ROS	9	рСРВ	Cold Crystalloid	•	11.1				11.1		
(2004)53	NOS	8	DHCA	Cold Crystalloid	·	0.0			·	12.5		
Palombo <i>et al.</i> (2004) <sup>54</sup>	ROS	7	рСРВ	Warm Blood	•	0.0			•	5.9		
Fleck <i>et al.</i> (2005) <sup>55</sup>	ROS	17	LHB	Cold Crystalloid	•	12.0			•	0.0		
Soukiasian <i>et al.</i>	DOC	39	DHCA		_	0.0	0.04	_		5.0		√
(2005)56	RUS	20	LHB		•	15.0	0.04	•		20.0		
Fehrenbacher <i>et</i> al. (2007) <sup>57</sup>	ROS	173	DHCA	Cold Blood	•	1.2			•	4.0		
Fehrenbacher <i>et</i> al. (2007) <sup>58</sup>	ROS	33	DHCA	Cold Blood	•	0.0			•	3.0		

Kunihara <i>et al.</i> (2009) <sup>59</sup>	POS	17	рСРВ	Warm Blood	•		0.0			•	0.0	
LeMaire <i>et al.</i> (2009) <sup>60</sup>	СТ	86 86	LHB LHB	Cold Blood Cold Crystalloid	•		3.0 3.0		•		7.0 5.0	
Fehrenbacher <i>et</i> <i>al.</i> (2010) <sup>61</sup>	ROS	343	DHCA		•		1.5		•		4.4	
Conrad <i>et al.</i> (2011) <sup>62</sup>	ROS	52 127	LHB SACC	Cold Crystalloid		•	8.0 17.0	NS		•	2.0 5.0	
Kulik <i>et al.</i> (2011) <sup>63</sup>	ROS	218	DHCA		•		6.9		•		7.3	
Corvera <i>et al.</i> (2012) <sup>64</sup>	ROS	93	DHCA	Cold Blood	•		0.0			•	2.2	
Weiss <i>et al.</i> (2012) <sup>65</sup>	ROS	45 28	DHCA pCPB		•		0.0 7.1	NS	•		8.9 7.1	V
Kouchoukos <i>et al.</i> (2013) <sup>66</sup>	ROS	243	DHCA		•		3.6		•		7.8	
Tshomba <i>et al.</i> (2014) <sup>5</sup>	ROS	42	LHB (88.9%), SACC (11.1%)	Cold Crystalloid	•		2.4		•		9.5	
(2014)		42	(84.4%), SACC (15.6%)	Cold HTK			7.2				2.4	$\checkmark$
Kouchoukos <i>et al.</i> (2015) <sup>67</sup>	ROS	69	DHCA		•		4.5		•		5.8	
Wongkornrat <i>et</i> al. (2015) <sup>68</sup>	ROS	200	LHB	Cold Crystalloid	•		2.5		•		3.0	

Zhang <i>et al.</i> (2016) <sup>69</sup>	ROS	81	DHCA		•	7.4		•	7.4		
Wahlgren <i>et al.</i> (2017) <sup>70</sup>	ROS	57 33	LHB DHCA	Cold Blood	•	33.0 15.0	•		10.5 6.1		
Alfonsi <i>et al.</i> (2018) <sup>71</sup>	ROS	173 41	LHB DHCA	Cold Crystalloid	•	4.6 7.3	•		5.2 9.7		
Mkalaluh <i>et al.</i> (2018) <sup>72</sup>		38	pCPB (84.2%), DHCA (15.8%)	Warm Blood	•	10.5	•		10.5		
Kouchoukos <i>et al.</i> (2019) <sup>73</sup>	ROS	285	DHCA		•	6.3	•		7.4		
Zhang <i>et al.</i> (2019) <sup>74</sup>	ROS	58 58	DHCA pCPB		•	13.8 3.4	•		6.9 0.0	<0.05	
Harky <i>et al.</i> (2021) <sup>75</sup>	ROS	273	LHB, DHCA (ratio not reported)	Cold Blood	•	22.7	•		9.9		
Kahlberg <i>et al.</i> (2021) <sup>14</sup>	СТ	45 45	LHB LHB	Cold HTK Cold Crystalloid	•	2.3 13.6	•		6.7 13.3		√
Kunihara <i>et al.</i> (2021) <sup>76</sup>	ROS	182	LHB (86.8%), DHCA (13.2%)	Warm Blood	•	12.1	•		11.0		
Bianchi <i>et al.</i> (2022) <sup>77</sup>	POS	100	LHB (84%), SACC (16%)			• 8.0		•	8.0		

Henmi <i>et al.</i> (2022) <sup>78</sup>	ROS	281	pCPB (86.5%), DHCA (13.5%)	Warm Blood	•	12.8		•	8.2	
Huang <i>et al.</i> (2022) <sup>79</sup>	ROS	26	LHB	Cold Crystalloid/HTK		7.7	•		15.4	
Karlsson <i>et al.</i> (2022) <sup>80</sup>	POS	21 12	LHB LHB	Cold Blood Cold Blood	•	33.0 8.0		•	5.0 0.0	
Sun <i>et al.</i> (2024) <sup>81</sup>	ROS	40	рСРВ		•	5.0	•		7.5	

AKI- Acute kidney injury, CT= Clinical trial, DHCA= Deep hypothermic circulatory arrest, HTK= Histidine-tryptophan-ketoglutarate, LHB= Left heart bypass, NS= Not significant, pCPB= Partial cardiopulmonary bypass, POS= Prospective observational study, ROS= Retrospective observational study, RRT= Renal replacement therapy, SACC= Simple aortic cross clamping, SRP= Selective renal perfusion. <sup>1</sup>= No pressure monitoring. <sup>2</sup>= Pressure monitoring. <sup>3</sup>=Roller pump. <sup>4</sup>=Centrifugal pump.

## **Outcome Measures**

# Acute Kidney Injury

Several different metrics were identified for the diagnosis of AKI. Post-operative RRT was the most common outcome measure, reported in 39 out of 45 (86.6%) studies, whereas alternative forms of diagnosis were described in 16 (35.5%); these were diverse, and included the use of KDIGO criteria, serum creatinine changes and undefined 'acute renal failure'. RIFLE or AKIN criteria were not used in any studies. As the incidence of RRT was reported in a majority of studies, it was selected as the primary endpoint for AKI. 'Other' AKI endpoints were recorded in the absence of RRT reporting, to facilitate the appropriate comparison of renal injury between cohorts within individual studies. 'Additional' evidence of renal protection was reported for studies that included more than one form of renal outcome assessment.

# **Operative Mortality**

30-day post-operative mortality was reported in 25 of 45 (55.6%) studies, and 'in-hospital mortality' in 18 (40.0%) studies. Both terms are referred to as 'operative mortality' in this review. 2 (4.4%) studies did not report mortality outcomes.

Table 5. Reported contents of renal perfusates containing crystalloid solutions												
Study	Blood	НТК	Mannitol	Methylprednisolone	Ringer's Acetate	Ringer's Lactate	Undefined					
Schepens <i>et al.</i> (1999)			•		•							
Koksoy <i>et al.</i> (2002)			•	•		•						
Nishi <i>et al.</i> (2004)							•					
Fleck <i>et al.</i> (2005)			•	•		•						
LeMaire <i>et al.</i> (2009)	•		•	•		•						
Conrad <i>et al</i> . (2011)			•	•		•						
Tshomba <i>et al.</i> (2014)		•	•	•		•						
Wongkornrat et al. (2015)							•					
Alfonsi <i>et al.</i> (2018)			•	•	٠							
Kahlberg <i>et al</i> . (2021)		•	•	•		•						
Huang <i>et al.</i> (2022)		•	•	•		•						
			HTK- Histidine	e Tryptophan Ketoglutara	te							

# Outcomes by Perfusion Strategy

Renal and mortality endpoints associated with each study subgroup are presented in table 4. Where a single circulatory support technique was used for over 75% of patients per study subgroup, renal and mortality endpoints and displayed in figures 6 & 7 by the predominant technique used.

## Distal Aortic Perfusion: Left Heart Bypass

The use of LHB *without* adjunctive SRP was associated with a 13.3-40.0% incidence of post-operative RRT, and a 0-20.0% risk of operative mortality. When used *with* adjunctive SRP, LHB was associated with incidences of RRT ranging from 5.0% to 33.0% with the use of normothermic blood, 3.0% to 33.0% with cold blood, and 0% to 13.6% with cold crystalloid solutions. Operative mortality ranged from 6.3% to 22.0% with the use of warm blood SRP, 5.7% to 10.5% with cold blood, and 0% to 15.4% with cold crystalloid solutions.

Four studies demonstrated that LHB can be used to achieve outcomes superior to SACC. Bavaria and colleagues showed that LHB was associated with a reduced incidence of in-hospital mortality (6.7% vs 22.2%, p<0.05)<sup>41</sup>. Schepens and colleagues found that the odds of requiring post-operative RRT were 92% lower with LHB than SACC (O.R. 0.08, 95%C.I. 0.01-0.6, p=0.02)<sup>47</sup>. LHB was also associated with a lower incidence of operative mortality (5.9% vs 14.6%, p<0.02)<sup>47</sup>. LeMaire and colleagues demonstrated that LHB could improve rates of AKI compared to SACC (9% vs 32%, p<0.0005), despite the adjunctive use of cold crystalloid SRP alongside SACC. This protection was also associated with non-significant reductions in RRT (3% vs 13%, p=0.167) and 30-day mortality (6% vs 22%)<sup>50</sup>. Similarly, Conrad and colleagues (2011) utilised propensity-matching to show that AKI (8% vs 17%, p=0.10) and in-hospital mortality (2% vs 5%, p=0.38) were lower with LHB than SACC with cold crystalloid SRP. However, their findings did not reach statistical significance<sup>62</sup>. Together, these findings support the use of DAP for the amelioration of renal IRI.

The use of SRP has been employed alongside LHB in several studies, to varying degrees of success. Warm blood SRP is generally associated with inferior outcomes, whereas selective renal cooling has been shown to provide effective kidney protection. In 1996, Safi and colleagues compared LHB with warm blood SRP to a non-adjunctive strategy of LHB, and identified warm blood SRP as a risk factor for AKI, associated with a four-fold increase in its incidence<sup>42</sup>. The mean collective blood flow was 250ml/min, shared between the renal and visceral arteries. Similarly, Koksoy and colleagues compared warm blood SRP to cold crystalloid SRP during LHB to find that warm blood SRP was associated with a three-fold rise in AKI (63% vs 21%, p=0.03)<sup>40</sup>. Hassoun and colleagues (2004) compared the use of warm and cold blood SRP during LHB, discovering that cold blood SRP was associated with a significantly lower incidence of operative mortality (27% vs 56%, p<0.02), despite no significant differences in recovery from renal dysfunction during hospitalisation (27% warm vs 36% cold, p=0.37)<sup>51</sup>. In a 2009 clinical trial, LeMaire and colleagues compared intermittent boluses of cold blood or crystalloid solution with additives mannitol and methylprednisolone during LHB. They found that the rate of RRT was identical in both cohorts (3.0% vs 3.0%, p=1.0), and there was no difference in the incidence of 30-day mortality (7.0% blood vs 5.0% crystalloid, p=0.7)<sup>60</sup>. Thus, there is strong evidence that renal cooling with blood or crystalloid solutions provides equivalent protection from IRI.

Furthermore, the contents of crystalloid perfusates can affect kidney protection. In a 2021 clinical trial, Kahlberg and colleagues compared the use of HTK solution to a Ringer's-based crystalloid perfusate, and demonstrated a lower incidence of KDIGO AKI with HTK solution (48.9% vs 75.6%, p=0.02), though rates of RRT were lower but not significantly different (2.2% vs 13.3%, p=0.11)<sup>14</sup>. Additionally, no significant difference in 30-day mortality was identified (6.7% HTK vs 13.3% Ringer's, p=0.23)<sup>14</sup>.

# Distal Aortic Perfusion: Partial Cardiopulmonary Bypass

The use of pCPB *without* SRP was associated with a 3.4-7.1% incidence of post-operative RRT and a 0-7.1% risk of operative mortality. pCPB with adjunctive warm blood SRP was associated with a 0-22.2% incidence of RRT. One study that utilised cold crystalloid SRP was associated with 11.1% incidences of RRT and inhospital mortality.

Like LHB, the use of pCPB can provide superior renal protection than SACC. Morishita and colleagues demonstrated that pCPB with adjunctive warm blood SRP could be used to significantly reduce the risk of RRT, irrespective of the type of blood pump used for circulatory support (4.5% centrifugal pump, 4.9% roller pump, 20% SACC, p=0.01). pCPB was also associated with higher intraoperative urine production (2.9ml/hr roller SRP, 2.8ml/hr centrifugal SRP, 0.2ml/hr SACC) and lower post-operative serum creatinine concentrations (p<0.0001) than SACC<sup>46</sup>. With a small cohort of patients, Kunihara and colleagues (2009) achieved no incidences of RRT or operative mortality with pCPB and warm blood SRP<sup>59</sup>. More recently, Henmi and colleagues (2022) analysed the results from 281 cases to show that 150-200ml/min of warm blood SRP per renal artery was associated with a 12.8% incidence of RRT, a 63.3% incidence of KDIGO AKI and an 8.2% risk of in-hospital mortality<sup>78</sup>. Notably, this study included a high (84.6%) incidence of preoperative renal dysfunction.

A propensity-matched comparison study from Weiss and colleagues (2012) found no significant difference in the rate of RRT following pCPB or DHCA, though DHCA was associated with a lower incidence of AKI (22.2% vs 46.4%, p=0.03)<sup>65</sup>. Notably, a higher proportion of DHCA patients received DTA repair (22% vs 42%, p=0.04), which is generally associated with reduced renal ischaemic times than TAA repair. Similarly, a propensity-matched study by Zhang and colleagues (2019) compared pCPB to DHCA and showed that whilst pCPB was associated with lower risks of RRT (3.4% vs 13.8%, p=0.047) and 30-day mortality (0% vs 6.9%, p<0.05), there was no significant difference in the rate of new-onset renal insufficiency (13.8% vs 24.1%, p=0.126)<sup>74</sup>.

# Deep Hypothermic Circulatory Arrest

The use of DHCA is associated with low incidences of RRT (0-15.0%) and operative mortality (2.2-12.5%). Soukiasian and colleagues (2005) compared DHCA to LHB and demonstrated that a reduced incidence of AKI, defined by a 1.5-fold increase in serum creatinine concentration, was associated with DHCA (0% vs 15%, p=0.04)<sup>56</sup>. Wahlgren and colleagues (2017) compared the use of DHCA with LHB and cold blood SRP, but found no significant differences in rates of AKI or 30-day mortality<sup>70</sup>. Consequently, there is evidence to suggest that DHCA can provide a high standard of renal protection. However, despite several studies of reasonable sample size, no study on DHCA was judged to present high-quality evidence (figure 5). Further prospective research into the effect of DHCA on kidney protection is therefore warranted, to facilitate the appropriate review of this technique.



Figure 6. The reported incidence of post-operative renal replacement therapy by study subgroup, according to strategies of circulatory support and selective renal perfusion. DHCA- cardiopulmonary bypass with deep hypothermic circulatory arrest; LHB- left heart bypass; pCPB- partial cardiopulmonary bypass; SRP- selective renal perfusion.



Figure 7. The reported incidences of 30-day and in-hospital mortality by study subgroup, according to strategies of circulatory support and selective renal perfusion. DHCA- cardiopulmonary bypass with deep hypothermic circulatory arrest; LHB- left heart bypass; pCPB- partial cardiopulmonary bypass; SRP- selective renal perfusion.

## Discussion

Surgical repair of the TAA is a life-saving procedure complicated by high risks of AKI and operative mortality. Addressing these issues requires the use of effective intraoperative kidney protection strategies. This systematic review assesses the findings of 45 published studies to identify the incidences of AKI and operative mortality by different perfusion techniques. Furthermore, through quality and risk of bias analysis, we evaluate the strength of evidence supporting the use of each technique.

The findings of this review should be interpreted with caution due to the limited number of studies deemed to present high or very-high quality evidence. The majority of studies were judged to be low quality, with 35 studies being of retrospective design and 23 featuring a single patient cohort. Just three randomised clinical trials have been conducted in this field, and with the evident heterogeneity in patient characteristics and operative techniques, we were limited in our ability to directly compare the efficacy of alternative perfusion strategies. Furthermore, the 29-year time period within which the included studies were published was host to an evolution in the criteria used to define AKI. Study endpoints therefore demonstrate a considerable level of variability.

Despite these constraints, several key themes emerged within our analysis of moderate to very-high quality studies:

- (1) Distal aortic perfusion provides effective kidney protection
- (2) Adjunctive renal cooling can enhance kidney protection during extensive TAA repairs
- (3) Warm selective renal perfusion provides inferior kidney protection
- (4) Deep hypothermic circulatory arrest provides promising kidney protection, but requires further clinical investigation

# 1. DAP provides effective kidney protection

Normothermic to mild hypothermic perfusion of the distal aorta provides superior kidney protection than SACC. LHB and pCPB can both provide DAP, perfuse the renal arteries during suprarenal aortic clamping and reduce exposure of the kidneys to IRI. During repairs of the DTA or extent I TAA, DAP can maintain kidney perfusion for the duration of surgery, eliminating renal IRI, as clamping of the infrarenal aorta is not required. During the repair of Crawford extent II-IV aneurysms, however, infra-renal clamping is necessary, meaning that renal IRI is unlikely to be avoided with an isolated strategy of DAP. The combined use of sequential aortic clamping may help to reduce renal ischaemic time<sup>21</sup>.

# 2. Adjunctive Renal Cooling can enhance Kidney Protection during extensive TAA repairs

When DAP cannot prevent kidney ischaemia, the renal arteries may be directly cannulated to facilitate perfusion of the kidneys with blood or crystalloid solutions. SRP may feature normothermic blood to support kidney oxygenation, or cold perfusates to enable hypothermic renal protection. Hypothermia is an established cryoprotection strategy, used during cardiopulmonary bypass to reduce cellular metabolism and associated oxygen demands<sup>82</sup>.

Our findings demonstrate that cold blood and crystalloid solutions - generally composed of lactated Ringer's solution, mannitol and methylprednisolone - can deliver equivalent protection from AKI and operative mortality<sup>60</sup>. Moreover, the use of HTK solution can further improve protection, and is linked to a low incidence of post-operative RRT<sup>14</sup>. However, such strategies should be used with care, as extensive cold crystalloid perfusion is associated with risks of systemic hypothermia and haemodilution, and may expose patients to an increased risk of cardiac arrest during surgery. Furthermore, this risk may be augmented with HTK solution, which is cardioplegic in nature, and could cause systemic hyponatraemia, arrhythmias or cardiac arrest if managed inappropriately. Finally, cold fluids also expose the kidneys to a sudden warm, highly oxygenated environment on reperfusion, which is theorised to exacerbate renal injury<sup>83</sup>. Whilst cold SRP can therefore be used to improve renal protection and reduce the incidence of AKI following surgery, it should be used with care. There is currently no professional guidance on the management of HTK solution for kidney protection, and further research into its safe and effective use is advised.

# 3. Warm Blood Selective Renal Perfusion provides inferior kidney protection

The theoretical advantages of normothermic blood SRP include functional protection of the kidneys and a reduced risk of cardiac arrest. However, our findings demonstrate that its use is associated with inferior renal protection and increased mortality. Several studies conducted out of Houston, Texas collectively illustrate that warm blood SRP used during LHB provides poor renal protection<sup>40, 42, 51</sup>. Similarly, whereas warm blood SRP used alongside pCPB may provide superior kidney protection than SACC<sup>46</sup>, a majority of patients still develop KDIGO AKI<sup>78</sup>.

It is likely that historic applications of warm SRP were performed sub-optimally. The kidneys are metabolically active organs that typically receive a combined blood flow of 1200ml/min in normal physiology<sup>84</sup>. Within the studies of this review, the maximum reported flow provided to the kidneys was 300ml/min per artery<sup>40</sup>. Furthermore, studies typically employed the use of a branched catheter system to enable simultaneous perfusion of the superior mesenteric and celiac arteries, which could lead to preferential flow away from the kidneys due to high relative renal resistance or narrow renal perfusion cannulae. It is feasible that flow rates used in these studies did not provide a sufficient delivery of oxygen to meet the metabolic demands of the kidneys at normothermia. Within the related discipline of ex vivo renal perfusion for transplantation, Weissenbacher and colleagues have achieved functional normothermic perfusion of human kidneys for 24 hours at a mean flow of 364ml/min per kidney, producing a mean urine output of 27.4ml/hr<sup>85</sup>. This represents a higher flow than that used in any of the studies included in this review. Whilst the clinical impact of normothermic perfusion cannot be determined from the results of Weissenbacher's study, the findings demonstrate that adequate blood flow can sustain functional protection. Furthermore, the incorporation of pulsatile flow may offer an additional advantage to kidney perfusion, but also requires further research and development prior to clinical implementation<sup>86, 87</sup>.

In TAA surgery, SRP cannot be continued for the entire duration of surgery, and must be stopped during reattachment of the renal arteries. During this time period, a warm kidney will be exposed to a greater degree of IRI than a kidney protected by a cold preservation solution. A combined strategy of functional, normothermic SRP followed by a bolus of hypothermic perfusate may provide effective intraoperative kidney protection. Without further pre-clinical optimisation, the results of this review do not support the use of warm SRP for kidney protection.

# 4. DHCA requires further clinical investigation

The establishment of deep hypothermia can reduce global metabolic demand and enable arrest of the systemic circulation<sup>88</sup>. Several studies demonstrate incidences of AKI comparable to the use of LHB with cold crystalloid SRP, suggesting that DHCA is an encouraging technique for kidney protection. However, the evidence for the use of DHCA is restricted to retrospective observational studies from a limited number of surgical centres. Furthermore, additional clinical outcomes and implications should be considered in the evaluation of novel care practices, and the use of DHCA is reportedly linked to higher rates of post-operative bleeding, stroke, low cardiac output syndrome and prolonged ventilator support than normothermic DAP<sup>7, 89</sup>. Moreover, within this series of reviewed papers, DHCA was the only circulatory support strategy not capable of achieving a 0% rate of operative mortality. Prospective research into the use of DHCA is recommended in order to determine the full implications of its use.

# Intravascular Haemolysis and Myoglobinaemia

Evidently, the use of any perfusion strategy is limited in its ability to protect patients from AKI. Whilst clamp-induced renal IRI is understood to be the primary cause of AKI, additional risk factors are known to contribute to its onset, and should be considered in any comprehensive package of renal protection. Importantly, high concentrations of circulating hemeproteins, such as haemoglobin and myoglobin, are associated with impaired post-operative renal function.

In 2022, Kiser and colleagues identified the intensive use of cell salvage during LHB as a risk factor for AKI and operative mortality<sup>90</sup>. The common strategy of reinfusing unwashed, salvaged blood into the patient circulation is a likely cause of significant intravascular haemolysis. Cardiotomy suction causes red blood cell damage and the release of free haemoglobin into plasma. Elevated free haemoglobin concentration has been identified as a risk factor for AKI following cardiopulmonary bypass for TAA repair, and Extra-Corporeal Membrane Oxygenation (ECMO)<sup>4, 30</sup>. Plasma free haemoglobin can scavenge nitric oxide present within the renal vascular endothelium, inhibit vasodilation and augment renal ischaemia. Furthermore, heme, a product of haemoglobin oxidation, has been shown to cause direct proximal tubular cell toxicity, and can trigger an inflammatory cascade leading to cell damage<sup>3, 35</sup>. Haemolysis may therefore contribute to AKI via renal endothelial dysfunction, cellular toxicity and amplification of the inflammatory response to surgery. Similarly, myoglobinaemia, caused by ischaemia of the femoral arteries, is known to contribute to AKI<sup>91, 92</sup>. The integration of perfusion techniques that minimise blood damage and peripheral ischaemia are therefore key to providing a holistic system of care that reduces renal hypoxia and toxicity.

## **Study Limitations**

Whilst this review provides a comprehensive analysis of published studies on renal protection during TAA surgery, its findings should be interpreted within the context of its inherent limitations. For example, results are limited to a crude analysis of renal and mortality outcomes subject to variations in patient characteristics, variability in the quality of reported details, and inconsistent AKI diagnosis criteria. Furthermore, no other morbidities, nor long-term mortality outcomes were analysed, but should be incorporated in any rigorous system of clinical decision-making. Similarly, we do not analyse certain surgical practices that may influence renal outcomes, such as patch vs Coselli graft repairs or the use of sequential clamping, renal stenting or endarterectomy. Nor do we include an analysis of warm renal ischaemic times, due to a general scarcity in the reporting of this information. Finally, whilst clinical outcomes were independently extracted and judged for consensus by two reviewers, the screening and quality assessment stages were performed by a single reviewer who adhered to a pre-determined set of screening questions (JB).

## Conclusion

AKI is a common concern following TAA surgery and is linked to an increased risk of operative mortality. Whilst the pathophysiology of AKI is multifactorial, it is commonly stimulated by clamp-induced renal IRI, which may be compounded by intravascular haemolysis and myoglobinaemia. The evidence from our analysis supports the use of distal aortic perfusion for extent I TAA repairs, and adjunctive cold SRP with HTK solution for extent II, III and IV TAA repairs. Normothermic SRP cannot be advocated on the basis of this review, but warrants pre-clinical investigation. Cardiopulmonary bypass with DHCA is an alternative strategy that may be capable of providing an excellent kidney protection, however, its use is supported by low-quality evidence and may be associated with additional adverse outcomes. Further, high-quality comparative research is necessary to establish its efficacy and limitations in relation to DAP and SRP.

# **References**

- 1. Zafar MA, Chen JF, Wu J, Li Y, Papanikolaou D, Abdelbaky M, et al. Natural history of descending thoracic and thoracoabdominal aortic aneurysms. *J Thorac Cardiovasc Surg*. 2021;161:498-511 e491
- 2. Hong JC, Coselli JS. Open repair remains the gold standard. JTCVS Tech. 2021;10:16-23
- 3. Hanssen SJ, Derikx JP, Vermeulen Windsant IC, Heijmans JH, Koeppel TA, Schurink GW, et al. Visceral injury and systemic inflammation in patients undergoing extracorporeal circulation during aortic surgery. *Annals of surgery*. 2008;248:117-125
- 4. Vermeulen Windsant IC, Snoeijs MG, Hanssen SJ, Altintas S, Heijmans JH, Koeppel TA, et al. Hemolysis is associated with acute kidney injury during major aortic surgery. *Kidney international*. 2010;77:913-920
- 5. Tshomba Y, Kahlberg A, Melissano G, Coppi G, Marone E, Ferrari D, et al. Comparison of renal perfusion solutions during thoracoabdominal aortic aneurysm repair. *J Vasc Surg*. 2014;59:623-633

- 6. Lampridou S, Saghdaoui LB, Bicknell C, Kumlien C, Lear R. Health related quality of life following intervention for thoracoabdominal aortic aneurysm: A systematic review and narrative synthesis. *Ann Vasc Surg.* 2024;101:105-119
- 7. Whitlock RS, Coselli JS. Review: Perspectives on renal and visceral protection during thoracoabdominal aortic aneurysm repair. *Indian J Thorac Cardiovasc Surg*. 2019;35:179-185
- 8. Keyhani K, Miller CC, 3rd, Estrera AL, Wegryn T, Sheinbaum R, Safi HJ. Analysis of motor and somatosensory evoked potentials during thoracic and thoracoabdominal aortic aneurysm repair. *J Vasc Surg*. 2009;49:36-41
- 9. Kemp CM, Feng Z, Aftab M, Reece TB. Preventing spinal cord injury following thoracoabdominal aortic aneurysm repair: The battle to eliminate paraplegia. *JTCVS Tech*. 2021;8:11-15
- 10. Coselli JS, LeMaire SA. Left heart bypass reduces paraplegia rates after thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* 1999;67:1931-1934; discussion 1953-1938
- 11. Coselli JS, LeMaire SA, Koksoy C, Schmittling ZC, Curling PE. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: Results of a randomized clinical trial. *J Vasc Surg.* 2002;35:631-639
- 12. Safi HJ, Miller CC, 3rd, Huynh TT, Estrera AL, Porat EE, Winnerkvist AN, et al. Distal aortic perfusion and cerebrospinal fluid drainage for thoracoabdominal and descending thoracic aortic repair: Ten years of organ protection. *Annals of surgery*. 2003;238:372-380; discussion 380
- 13. Tshomba Y, Simonini E, Colombo E, Ardita V, Apruzzi L, Rinaldi E, et al. Renal perfusion during aortic surgery: Looking for the ideal substrate. *Visceral vessels and aortic repair*. 2019:195-205.
- 14. Kahlberg A, Tshomba Y, Baccellieri D, Bertoglio L, Rinaldi E, Ardita V, et al. Renal perfusion with histidine-tryptophan-ketoglutarate compared with ringer's solution in patients undergoing thoracoabdominal aortic open repair. *J Thorac Cardiovasc Surg*. 2021:-
- 15. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the rifle criteria for acute renal failure in hospitalized patients. *Crit Care Med*. 2006;34:1913-1917
- 16. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. *The Journal of clinical investigation*. 2011;121:4210-4221
- 17. Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: A kdigo summary (part 1). *Crit Care*. 2013;17:204
- 18. Levi TM, de Souza SP, de Magalhaes JG, de Carvalho MS, Cunha AL, Dantas JG, et al. Comparison of the rifle, akin and kdigo criteria to predict mortality in critically ill patients. *Rev Bras Ter Intensiva*. 2013;25:290-296
- 19. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. *American journal of nephrology*. 2012;35:349-355
- 20. Chatterjee S, LeMaire SA, Amarasekara HS, Green SY, Price MD, Yanoff MS, et al. Early-stage acute kidney injury adversely affects thoracoabdominal aortic aneurysm repair outcomes. *Ann Thorac Surg*. 2019;107:1720-1726
- 21. Waked K, Schepens M. State-of the-art review on the renal and visceral protection during open thoracoabdominal aortic aneurysm repair. *J Vis Surg.* 2018;4:31
- 22. Turgut F, Awad AS, Abdel-Rahman EM. Acute kidney injury: Medical causes and pathogenesis. *J Clin Med*. 2023;12
- 23. Aftab M, Coselli JS. Renal and visceral protection in thoracoabdominal aortic surgery. *J Thorac Cardiovasc Surg*. 2014;148:2963-2966
- 24. Rouer M, Monnot A, Bubenheim M, Fuda M, Godier S, Lebras M, et al. Early postoperative renal dysfunction predicts long-term renal function degradation after type iv thoracoabdominal aortic aneurysm surgical repair. *Ann Vasc Surg.* 2020;68:316-325
- 25. LeMaire SA, Price MD, Green SY, Zarda S, Coselli JS. Results of open thoracoabdominal aortic aneurysm repair. *Ann Cardiothorac Surg*. 2012;1:286-292

- 26. Monaco F, Gaia B, Cristina M, De Luca M. Physiopathology of intraoperative visceral ischemia and anesthesiological management of supravisceral aortic clamping. In: Tshomba Y, Baccellieri D, Chiesa R, eds. *Visceral vessels and aortic repair: Challenges and difficult cases*. Switzerland: Springer; 2019.
- 27. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. *Compr Physiol*. 2012;2:1303-1353
- 28. Yokoyama N, Nonaka T, Kimura N, Sasabuchi Y, Hori D, Matsunaga W, et al. Acute kidney injury following elective open aortic repair with suprarenal clamping. *Ann Vasc Dis*. 2020;13:45-51
- 29. Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: A review in search of a treatment algorithm. *J Extra Corpor Technol*. 2008;40:257-267
- 30. Vermeulen Windsant IC, de Wit NC, Sertorio JT, van Bijnen AA, Ganushchak YM, Heijmans JH, et al. Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage. *Front Physiol*. 2014;5:340
- 31. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. *Nat Rev Nephrol*. 2011;7:189-200
- 32. Schaub JA, Venkatachalam MA, Weinberg JM. Proximal tubular oxidative metabolism in acute kidney injury and the transition to ckd. *Kidney360*. 2021;2:355-364
- 33. Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. *Nat Rev Nephrol*. 2017;13:629-646
- 34. Welborn MB, Oldenburg SA, Hess PJ, Huber TS, Martin TD, Rauwerda JA, et al. The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair. *Crit Care Med*. 2000;28
- 35. Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. *J Renal Inj Prev*. 2015;4:20-27
- 36. Kashyap VS, Cambria RP, Davison JK, L'Italien GJ. Renal failure after thoracoabdominal aortic surgery. *J Vasc Surg*. 1997;26:949-955; discussion 955-947
- 37. Wynn MM, Acher C, Marks E, Engelbert T, Acher CW. Postoperative renal failure in thoracoabdominal aortic aneurysm repair with simple cross-clamp technique and 4 degrees c renal perfusion. *J Vasc Surg*. 2015;61:611-622
- 38. Safi HJ, Winnerkvist A, Miller CC, 3rd, Iliopoulos DC, Reardon MJ, Espada R, et al. Effect of extended cross-clamp time during thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg*. 1998;66:1204-1209
- 39. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Jr., et al. 2010 accf/aha/aats/acr/asa/sca/scai/sir/sts/svm guidelines for the diagnosis and management of patients with thoracic aortic disease: A report of the american college of cardiology foundation/american heart association task force on practice guidelines, american association for thoracic surgery, american college of radiology, american stroke association, society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, society of interventional radiology, society of thoracic surgeons, and society for vascular medicine. *Circulation*. 2010;121:e266-369
- 40. Köksoy C, LeMaire SA, Curling PE, Raskin SA, Schmittling ZC, Conklin LD, et al. Renal perfusion during thoracoabdominal aortic operations: Cold crystalloid is superior to normothermic blood. *Ann Thorac Surg.* 2002;73:730-738
- 41. Bavaria JE, Woo YJ, Hall RA, Carpenter JP, Gardner TJ. Retrograde cerebral and distal aortic perfusion during ascending and thoracoabdominal aortic operations. *Ann Thorac Surg.* 1995;60:345-352; discussion 352

- 42. Safi HJ, Harlin SA, Miller CC, Iliopoulos DC, Joshi A, Mohasci TG, et al. Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. *J Vasc Surg*. 1996;24:338-344; discussion 344-335
- 43. Jacobs MJ, Eijsman L, Meylaerts SA, Balm R, Legemate DA, de Haan P, et al. Reduced renal failure following thoracoabdominal aortic aneurysm repair by selective perfusion. *Eur J Cardiothorac Surg*. 1998;14:201-205
- 44. Leijdekkers VJ, Wirds JW, Vahl AC, van Genderingen HR, Siebenga J, Westerhof N, et al. The visceral perfusion system and distal bypass during thoracoabdominal aneurysm surgery: An alternative for physiological blood flow? *Cardiovasc Surg*. 1999;7:219-224
- 45. Mastroroberto P, Chello M. Emergency thoracoabdominal aortic aneurysm repair: Clinical outcome. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. 1999;118:477-481
- 46. Morishita K, Yokoyama H, Inoue S, Koshino T, Tamiya Y, Abe T. Selective visceral and renal perfusion in thoracoabdominal aneurysm repair. *Eur J Cardiothorac Surg*. 1999;15:502-507
- 47. Schepens MAAM, Vermeulen FEE, Morshuis WJ, Dossche KM, Van Dongen EP, Ter Beek HT, et al. Impact of left heart bypass on the results of thoracoabdominal aortic aneurysm repair. 1999
- 48. Cina CS, Lagana A, Bruin G, Ricci C, Doobay B, Tittley J, et al. Thoracoabdominal aortic aneurysm repair: A prospective cohort study of 121 cases. *Ann Vasc Surg*. 2002;16:631-638
- 49. Kawaharada N, Morishita K, Fukada J, Yamada A, Muraki S, Hyodoh H, et al. Thoracoabdominal or descending aortic aneurysm repair after preoperative demonstration of the adamkiewicz artery by magnetic resonance angiography. *Eur J Cardiothorac Surg*. 2002;21:970-974
- 50. LeMaire SA, Rice DC, Schmittling ZC, Coselli JS. Emergency surgery for thoracoabdominal aortic aneurysms with acute presentation. *J Vasc Surg*. 2002;35:1171-1178
- 51. Hassoun HT, Miller CC, 3rd, Huynh TT, Estrera AL, Smith JJ, Safi HJ. Cold visceral perfusion improves early survival in patients with acute renal failure after thoracoabdominal aortic aneurysm repair. *J Vasc Surg*. 2004;39:506-512
- 52. Kawaharada N, Morishita K, Fukada J, Hachiro Y, Takahashi K, Abe T. Thoracoabdominal aortic aneurysm repair through redo left-sided thoracotomy. *Ann Thorac Surg*. 2004;77:1304-1308
- 53. Nishi H, Miyamoto S, Minamimura H, Ishikawa T, Kato Y, Arimoto H, et al. Extensive thoracoabdominal aortic aneurysm repair using deep hypothermic bypass and circulatory arrest. 2004;12:69-74
- 54. Palombo D, Valenti D, Gaggiano A, Lupo M, Borin P. Early experience with the minimal extracorporeal circulation system (mecc) during thoracoabdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg*. 2004;27:324-326
- 55. Fleck TM, Koinig H, Moidl R, Czerny M, Hamilton C, Schifferer A, et al. Improved outcome in thoracoabdominal aortic aneurysm repair: The role of cerebrospinal fluid drainage. *Neurocrit Care*. 2005;2:11-16
- 56. Soukiasian HJ, Raissi SS, Kleisli T, Lefor AT, Fontana GP, Czer LS, et al. Total circulatory arrest for the replacement of the descending and thoracoabdominal aorta. *Arch Surg*. 2005;140:394-398
- 57. Fehrenbacher JW, Hart DW, Huddleston E, Siderys H, Rice C. Optimal end-organ protection for thoracic and thoracoabdominal aortic aneurysm repair using deep hypothermic circulatory arrest. *Ann Thorac Surg.* 2007;83:1041-1046
- 58. Fehrenbacher J, Siderys H, Shahriari A. Preservation of renal function utilizing hypothermic circulatory arrest in the treatment of distal thoracoabdominal aneurysms (types iii and iv). *Ann Vasc Surg.* 2007;21:204-207
- 59. Kunihara T, Shiiya N, Wakasa S, Matsuzaki K, Matsui Y. Assessment of hepatosplanchnic pathophysiology during thoracoabdominal aortic aneurysm repair using visceral perfusion and shunt. *Eur J Cardiothorac Surg*. 2009;35:677-683

- 60. Lemaire SA, Jones MM, Conklin LD, Carter SA, Criddell MD, Wang XL, et al. Randomized comparison of cold blood and cold crystalloid renal perfusion for renal protection during thoracoabdominal aortic aneurysm repair. *J Vasc Surg*. 2009;49:11-19; discussion 19
- 61. Fehrenbacher JW, Siderys H, Terry C, Kuhn J, Corvera JS. Early and late results of descending thoracic and thoracoabdominal aortic aneurysm open repair with deep hypothermia and circulatory arrest. *J Thorac Cardiovasc Surg*. 2010;140:S154-160; discussion S185
- 62. Conrad MF, Ergul EA, Patel VI, Cambria MR, Lamuraglia GM, Simon M, et al. Evolution of operative strategies in open thoracoabdominal aneurysm repair. *J Vasc Surg*. 2011;53:1195-1201 e1191
- 63. Kulik A, Castner CF, Kouchoukos NT. Outcomes after thoracoabdominal aortic aneurysm repair with hypothermic circulatory arrest. *J Thorac Cardiovasc Surg*. 2011;141:953-960
- 64. Corvera JS, Fehrenbacher JW. Open repair of chronic aortic dissections using deep hypothermia and circulatory arrest. *Ann Thorac Surg*. 2012;94:78-81; discussion 82-73
- 65. Weiss AJ, Lin HM, Bischoff MS, Scheumann J, Lazala R, Griepp RB, et al. A propensity scorematched comparison of deep versus mild hypothermia during thoracoabdominal aortic surgery. J Thorac Cardiovasc Surg. 2012;143:186-193
- 66. Kouchoukos NT, Kulik A, Castner CF. Outcomes after thoracoabdominal aortic aneurysm repair using hypothermic circulatory arrest. *J Thorac Cardiovasc Surg*. 2013;145:S139-141
- 67. Kouchoukos NT, Kulik A, Castner CF. Open thoracoabdominal aortic repair for chronic type b dissection. *J Thorac Cardiovasc Surg*. 2015;149:S125-129
- 68. Wongkornrat W, Yamamoto S, Sekine Y, Ono M, Fujikawa T, Oshima S, et al. Predictors of paraplegia with current thoracoabdominal aortic aneurysm repair. *Asian Cardiovasc Thorac Ann*. 2015;23:406-411
- 69. Zhang L, Sun XG, Yu CT, Chang Q, Qian XY. Intercostal artery reconstruction: The simple and effective technique on spinal cord protection during thoracoabdominal aortic replacement. *Ann Vasc Surg.* 2016;34:62-67
- 70. Wahlgren CM, Blohmé L, Günther A, Nilsson L, Olsson C. Outcomes of left heart bypass versus circulatory arrest in elective open surgical descending and thoraco-abdominal aortic repair. *Eur J Vasc Endovasc Surg.* 2017;53:672-678
- 71. Alfonsi J, Murana G, Smeenk HG, Kelder H, Schepens M, Sonker U, et al. Open surgical repair of post-dissection thoraco-abdominal aortic aneurysms: Early and late outcomes of a single-centre study involving over 200 patients. *Eur J Cardiothorac Surg*. 2018;54:382-388
- 72. Mkalaluh S, Szczechowicz M, Dib B, Weymann A, Szabo G, Karck M. Open surgical thoracoabdominal aortic aneurysm repair: The heidelberg experience. *J Thorac Cardiovasc Surg*. 2018;156:2067-2073
- 73. Kouchoukos NT, Kulik A, Haynes M, Castner CF. Early outcomes after thoracoabdominal aortic aneurysm repair with hypothermic circulatory arrest. *Ann Thorac Surg*. 2019;108:1338-1343
- 74. Zhang L, Yu C, Yang X, Sun X, Qiu J, Jiang W, et al. Normothermic iliac perfusion improves early outcomes after thoraco-abdominal aortic aneurysm repair. *Eur J Cardiothorac Surg*. 2019;55:1054-1060
- 75. Harky A, Othman A, Shaw M, Nawaytou O, Harrington D, Kuduvalli M, et al. Contemporary results of open thoracic and thoracoabdominal aortic surgery in a single united kingdom center. *J Vasc Surg*. 2021;73:1525-1532 e1524
- 76. Kunihara T, Vukic C, Sata F, Schafers HJ. Surgical thoracoabdominal aortic aneurysm repair in a nonhigh-volume institution. *Thorac Cardiovasc Surg*. 2021;69:347-356
- 77. Bianchi F, Cursi M, Caravati H, Butera C, Bosco L, Monaco F, et al. Intraoperative neurophysiologic monitoring in thoracoabdominal aortic aneurysm surgery can provide real-time feedback for strategic decision making. *Neurophysiol Clin*. 2022;52:232-241

- 78. Henmi S, Okita Y, Koda Y, Yamanaka K, Omura A, Inoue T, et al. Acute kidney injury affects midterm outcomes of thoracoabdominal aortic aneurysms repair. *Semin Thorac Cardiovasc Surg*. 2022;34:430-438
- 79. Huang L, Chen X, Hu Q, Luo F, Hu J, Duan L, et al. The application of modular multifunctional left heart bypass circuit system integrated with ultrafiltration in thoracoabdominal aortic aneurysm repair. *Front Cardiovasc Med*. 2022;9:944287
- 80. Karlsson L, Babaie-Khojini A, Blohme L, Daryapeyma A, Gunther A, Nilsson L, et al. Novel method for direct retransfusion reduces blood transfusions in descending and thoracoabdominal aneurysm repair. *J Cardiovasc Surg (Torino)*. 2022;63:700-707
- 81. Sun N, Pandey AK, Manchikanti S, Gupta A, Rajeev A, Muniswamy S, et al. Outcome of open repair of thoracoabdominal aortic aneurysm in takayasu arteritis: A retrospective analysis. *Ann Vasc Surg*. 2024;103:99-108
- 82. Saad H, Aladawy M. Temperature management in cardiac surgery. *Glob Cardiol Sci Pract*. 2013;2013:44-62
- 83. Hosgood SA, van Heurn E, Nicholson ML. Normothermic machine perfusion of the kidney: Better conditioning and repair? *Transpl Int*. 2015;28:657-664
- 84. Duke J. Renal function and anesthesia. *Anesthesia secrets*. Philadelphia, USA: Mosby Elsevier; 2011:308.
- 85. Weissenbacher A, Lo Faro L, Boubriak O, Soares MF, Roberts IS, Hunter JP, et al. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. *Am J Transplant*. 2019;19:178-192
- 86. von Horn C, Minor T. Isolated kidney perfusion: The influence of pulsatile flow. *Scand J Clin Lab Invest*. 2018;78:131-135
- 87. Moustafellos P, Hadjianastassiou V, Roy D, Muktadir A, Contractor H, Vaidya A, et al. The influence of pulsatile preservation in kidney transplantation from non-heart-beating donors. *Transplantation proceedings*. 2007;39:1323-1325
- 88. Conolly S, Arrowsmith JE, Klein AA. Deep hypothermic circulatory arrest. *Continuing Education in Anaesthesia Critical Care & Pain*. 2010;10:138-142
- 89. Yoo JS, Kim JB, Joo Y, Lee WY, Jung SH, Choo SJ, et al. Deep hypothermic circulatory arrest versus non-deep hypothermic beating heart strategy in descending thoracic or thoracoabdominal aortic surgery. *Eur J Cardiothorac Surg*. 2014;46:678-684
- 90. Kiser KA, Tanaka A, Sandhu HK, Miller CC, 3rd, Leonard SD, Safi HJ, et al. Extensive cell salvage and postoperative outcomes following thoracoabdominal and descending aortic repair. *J Thorac Cardiovasc Surg*. 2022;163:914-921 e911
- 91. Bisdas T, Redwan A, Wilhelmi M, Haverich A, Hagl C, Teebken O, et al. Less-invasive perfusion techniques may improve outcome in thoracoabdominal aortic surgery. *J Thorac Cardiovasc Surg*. 2010;140:1319-1324
- 92. Miller CC, 3rd, Grimm JC, Estrera AL, Azizzadeh A, Coogan SM, Walkes JC, et al. Postoperative renal function preservation with nonischemic femoral arterial cannulation for thoracoabdominal aortic repair. *J Vasc Surg*. 2010;51:38-42

**Acknowledgements** 

None

# Sources of Funding

Tuition fees for Mr Bennett's PhD are kindly paid by Liverpool Heart and Chest Hospital NHS Trust.

**Disclosures** 

None